Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4182817 | 0.90 | ADORA2A (0.40) | ADORA2AADORA1NR1H2NR1H3NT5E | |
| SCHEMBL27802879 | 0.88 | ADORA2A (0.39) | ADORA2AADORA1NR1H2NR1H3NT5E | |
| SCHEMBL4167700 | 0.88 | ADORA2A (0.39) | ADORA2AADORA1NR1H2NR1H3NT5E | |
| SCHEMBL17718352 | 0.85 | DHODH (0.41) | ADORA2ANR1H2NR1H3GAAMEN1 | |
| SCHEMBL4173758 | 0.85 | NR1H2 (0.40) | ADORA2AADORA1NR1H2NR1H3NT5E | |
| SCHEMBL4178794 | 0.84 | ABL1 (0.34) | NR1H2NR1H3DPP4ALDH1A1CYP1A2 | |
| SCHEMBL4182457 | 0.80 | NR1H2 (0.51) | ADORA2AADORA1NR1H2NR1H3NT5E | |
| SCHEMBL16447644 | 0.80 | ADORA2A (0.39) | ADORA2AADORA1NR1H2NR1H3NT5E | |
| SCHEMBL4181287 | 0.79 | PTGS2 (0.39) | ADORA2ANR1H2NR1H3PTGS2CTSA | |
| SCHEMBL10251324 | 0.79 | ADORA2A (0.39) | ADORA2AADORA1NT5EPTGS2CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3045458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2137186-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20120220585-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220585-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220585-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2137186-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008118468-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | ADORA2A 1368/4885ADORA1 3475/4885NR1H2 799/4885 |
| US-20090137581-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | ADORA2A 1368/4885ADORA1 3475/4885NR1H2 799/4885 |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | ADORA2A 1368/4885ADORA1 3475/4885NR1H2 799/4885 |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | ADORA2A 1368/4885ADORA1 3475/4885NR1H2 799/4885 |
| US-20120220585-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | ADORA2A 1368/4885ADORA1 3475/4885NR1H2 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.